Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations

被引:33
作者
Noreddin, AM
Roberts, D
Nichol, K
Wierzbowski, A
Hoban, DJ
Zhanel, GG
机构
[1] Hlth Sci Ctr, Dept Clin Microbiol, Winnipeg, MB R3A 1R9, Canada
[2] Hlth Sci Ctr, Dept Med, Winnipeg, MB R3A 1R9, Canada
[3] Univ Manitoba, Fac Med, Dept Med Microbiol, Winnipeg, MB, Canada
关键词
D O I
10.1128/AAC.46.12.4029-4034.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The association between macrolide resistance mechanisms and clinical outcomes remains understudied. The present study, using an in vitro pharmacodynamic model, assessed clarithromycin (CLR) activity against mef(A)-positive and erm (B)-negative Streptococcus pneumoniae isolates by simulating free-drug concentrations in serum and both total (protein-bound and free) and free drug in epithelial lining fluid (ELF). Five mef(A)positive and erm(B)-negative strains, one mef(A)-negative and erm(B)-positive strain, and a control [mef(A)negative and erm (B) -negative] strain of S.pneumoniae were tested. CLR was modeled using a one-compartment model, simulating a dosage of 500 mg, per os, twice a day (in serum, free-drug C-p maximum of 2 mug/ml, t(1/2) of 6 h; in ELF, C-ELF(total) maximum of 35 mug/ml, t(1/2) of 6 h; C-ELF(free) maximum of 14 mug/ml t(1/2) of 6 h). Starting inocula were 10(6) CFU/ml in Mueller-Hinton broth with 2% lysed horse blood. With sampling at 0, 4, 8, 12, 20, and 24 h, the extent of bacterial killing was assessed. Achieving CLR T/MIC values of greater than or equal to90% (AUC(0-24)/MIC ratio, greater than or equal to61) resulted in bacterial eradication, while T>MIC values of 40 to 56% (AUC(0-24)/MIC ratios of greater than or equal to30.5 to 38) resulted in a 1.2 to 2.0 log(10) CFU/ml decrease at 24 h compared to that for the initial inoculum. CLR T/MIC values of less than or equal to8% (AUC(0-24)/MIC ratio, less than or equal to17.3) resulted in a static effect or bacterial regrowth. The high drug concentrations in ELF that were obtained clinically with CLR may explain the lack of clinical failures with mef(A)-producing S. pneumoniae strains, with MICs up to 8 mug/ml. However, mef(A) isolates for which MICs are greater than or equal to16 mug/ml along with erm(B) may result in bacteriological failures.
引用
收藏
页码:4029 / 4034
页数:6
相关论文
共 34 条
[2]   Emerging resistance to antimicrobial agents in gram-positive bacteria - Pneumococci [J].
Appelbaum, PC .
DRUGS, 1996, 51 :1-5
[3]   Community-acquired pneumonia in adults: Guidelines for management [J].
Bartlett, JG ;
Breiman, RF ;
Mandell, LA ;
File, TM .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :811-838
[4]   The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: An update from the centers for disease control and prevention's pneumococcal sentinel surveillance system [J].
Butler, JC ;
Hofmann, J ;
Cetron, MS ;
Elliott, JA ;
Facklam, RR ;
Breiman, RF ;
Camp, C ;
Charache, P ;
Dern, R ;
Jackson, M ;
Hadley, WK ;
HoppeBauer, J ;
Jacobs, MR ;
Schreiber, J ;
Boxerbaum, B ;
Menuey, BC ;
Tyler, PG ;
Monahan, J ;
Moore, H ;
Siegel, JD ;
Sherer, D ;
Rogers, P ;
Welch, D ;
Fine, D ;
Radike, J ;
Fiore, A ;
Alexander, M ;
Deaver, K .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :986-993
[5]  
Campbell GD, 1998, CLIN INFECT DIS, V26, P1188, DOI 10.1086/520286
[6]   Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study [J].
ClavoSanchez, AJ ;
GironGonzalez, JA ;
LopezPrieto, D ;
CanuetoQuintero, J ;
SanchezPorto, A ;
VergaraCampos, A ;
MarinCasanova, P ;
CordobaDona, JA .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (06) :1052-1059
[7]   BACTERIOLOGY OF ACUTE OTITIS-MEDIA - A NEW PERSPECTIVE [J].
DELBECCARO, MA ;
MENDELMAN, PM ;
INGLIS, AF ;
RICHARDSON, MA ;
DUNCAN, NO ;
CLAUSEN, CR ;
STULL, TL .
JOURNAL OF PEDIATRICS, 1992, 120 (01) :81-84
[8]   Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995 [J].
Doern, GV ;
Heilmann, KP ;
Huynh, HK ;
Rhomberg, PR ;
Coffman, SL ;
Brueggemann, AB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1721-1729
[9]  
EHLUND GAC, 2000, J ANTIMICROB CHEMOTH, V46, P741
[10]   AN OVERVIEW OF NOSOCOMIAL INFECTIONS, INCLUDING THE ROLE OF THE MICROBIOLOGY LABORATORY [J].
EMORI, TG ;
GAYNES, RP .
CLINICAL MICROBIOLOGY REVIEWS, 1993, 6 (04) :428-442